CN102170865A - 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂 - Google Patents

具有二氟泼尼酯的黄斑水肿治疗用滴眼剂 Download PDF

Info

Publication number
CN102170865A
CN102170865A CN2010800027502A CN201080002750A CN102170865A CN 102170865 A CN102170865 A CN 102170865A CN 2010800027502 A CN2010800027502 A CN 2010800027502A CN 201080002750 A CN201080002750 A CN 201080002750A CN 102170865 A CN102170865 A CN 102170865A
Authority
CN
China
Prior art keywords
administration
eye drop
difluprednate
day
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800027502A
Other languages
English (en)
Chinese (zh)
Inventor
山下英俊
山本祯子
后藤早纪子
阿部佐知
桐井枝里子
奥村敦司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamagata University NUC
Original Assignee
Yamagata University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamagata University NUC filed Critical Yamagata University NUC
Priority to CN201710195879.3A priority Critical patent/CN107569494A/zh
Publication of CN102170865A publication Critical patent/CN102170865A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2010800027502A 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂 Pending CN102170865A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710195879.3A CN107569494A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-165924 2009-07-14
JP2009165924 2009-07-14
PCT/JP2010/062289 WO2011007893A1 (en) 2009-07-14 2010-07-14 Eye drop with difluprednate for macular edema treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710195879.3A Division CN107569494A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
CN201310288639.XA Division CN103705524A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂

Publications (1)

Publication Number Publication Date
CN102170865A true CN102170865A (zh) 2011-08-31

Family

ID=42646370

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010800027502A Pending CN102170865A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
CN201310288639.XA Withdrawn CN103705524A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
CN201710195879.3A Pending CN107569494A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201310288639.XA Withdrawn CN103705524A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
CN201710195879.3A Pending CN107569494A (zh) 2009-07-14 2010-07-14 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂

Country Status (13)

Country Link
US (3) US20110190250A1 (enExample)
EP (1) EP2340014B1 (enExample)
JP (1) JP5579079B2 (enExample)
KR (1) KR101689847B1 (enExample)
CN (3) CN102170865A (enExample)
BR (1) BRPI1005380A2 (enExample)
CA (1) CA2738151C (enExample)
ES (1) ES2405779T3 (enExample)
MX (1) MX2011005043A (enExample)
PL (1) PL2340014T3 (enExample)
RU (1) RU2572707C2 (enExample)
TW (1) TW201105363A (enExample)
WO (1) WO2011007893A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130859A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯晶型i及其制备方法
CN103130857A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯ⅱ晶型及其制备方法
CN105120875A (zh) * 2013-02-15 2015-12-02 千寿制药株式会社 包含锌的二氟泼尼酯乳液组合物
CN108014172A (zh) * 2017-12-29 2018-05-11 广州仁恒医药科技股份有限公司 一种含有二氟泼尼酯的药物组合物及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902100B2 (ja) * 2011-01-14 2016-04-13 株式会社エス・ディー・エス バイオテック ４−（３−ブチニル）アミノピリミジン誘導体を含む農園芸用有害生物防除剤組成物
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
WO2015197594A2 (de) 2014-06-23 2015-12-30 Schott Ag Elektrisches speichersystem enthaltend ein scheibenförmiges diskretes element, scheibenförmiges diskretes element sowie verfahren zu dessen herstellung und dessen verwendung
JP2018505515A (ja) 2014-12-01 2018-02-22 ショット アクチエンゲゼルシャフトＳｃｈｏｔｔ ＡＧ シート状の独立した部材を有する蓄電システム、独立したシート状の部材、その製造方法、およびその使用
EP4566638A3 (en) * 2015-05-29 2025-08-27 Allergan, Inc. Implant for treatment of an ocular condition
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
KR20210012346A (ko) 2019-07-25 2021-02-03 심낙범 미세먼지 눈꺼풀 세정스틱
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
WO2021050649A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878197A1 (en) * 1997-05-14 1998-11-18 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3781792B2 (ja) 1993-12-27 2006-05-31 千寿製薬株式会社 ジフルプレドナート含有点眼用懸濁液剤
AU684115B2 (en) 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
MXPA05008561A (es) * 2003-02-20 2005-11-04 Alcon Inc Uso de esteroides para tratar personas que sufren de trastornos oculares.
US20050226814A1 (en) * 2004-04-13 2005-10-13 Bausch & Lomb Incorporated Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid
US20060009498A1 (en) * 2004-07-12 2006-01-12 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
US20070049568A1 (en) 2005-08-25 2007-03-01 Psivida Inc. Control of induced elevated intraocular pressure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878197A1 (en) * 1997-05-14 1998-11-18 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130859A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯晶型i及其制备方法
CN103130857A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯ⅱ晶型及其制备方法
CN103130859B (zh) * 2011-11-30 2015-12-02 天津金耀集团有限公司 二氟泼尼酯晶型i及其制备方法
CN105120875A (zh) * 2013-02-15 2015-12-02 千寿制药株式会社 包含锌的二氟泼尼酯乳液组合物
CN105120875B (zh) * 2013-02-15 2018-01-09 千寿制药株式会社 包含锌的二氟泼尼酯乳液组合物
CN108014172A (zh) * 2017-12-29 2018-05-11 广州仁恒医药科技股份有限公司 一种含有二氟泼尼酯的药物组合物及其制备方法

Also Published As

Publication number Publication date
ES2405779T3 (es) 2013-06-03
US20110190250A1 (en) 2011-08-04
EP2340014B1 (en) 2013-04-24
KR20120040683A (ko) 2012-04-27
CN103705524A (zh) 2014-04-09
RU2011125640A (ru) 2013-08-20
CN107569494A (zh) 2018-01-12
EP2340014A1 (en) 2011-07-06
CA2738151C (en) 2017-02-28
US20180133153A1 (en) 2018-05-17
US9949926B2 (en) 2018-04-24
WO2011007893A1 (en) 2011-01-20
JP2012533517A (ja) 2012-12-27
KR101689847B1 (ko) 2016-12-26
PL2340014T3 (pl) 2013-09-30
RU2572707C2 (ru) 2016-01-20
BRPI1005380A2 (pt) 2016-02-10
US10092514B2 (en) 2018-10-09
US20150190340A1 (en) 2015-07-09
MX2011005043A (es) 2011-06-01
TW201105363A (en) 2011-02-16
JP5579079B2 (ja) 2014-08-27
CA2738151A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CN102170865A (zh) 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
EP3681500B2 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
KR100723189B1 (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
KR102177199B1 (ko) 안저질환 치료제
Fathilah et al. The Jarisch-Herxheimer reaction in ocular syphilis
CN115066236A (zh) 糖尿病性黄斑水肿和视敏度受损的治疗
Hollo et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma
JP2015523986A5 (enExample)
Kiland et al. Effect of timolol maleate gel‐forming solution on intraocular pressure, pupil diameter, and heart rate in normal and glaucomatous cats
WO2012068998A2 (zh) 一种曲安奈德眼用制剂及其制备方法
CN115957216B (zh) 眼用制剂及其制备方法和用途
Steigerwalt et al. Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids
CN118510520A (zh) 用于治疗眼部疾病的霉酚酸和/或倍他米松的药物组合物
Wirta et al. Double-Masked, Vehicle-Controlled, Randomized, Phase II Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution
CN103405766B (zh) 一种贝伐单抗滴眼液及其制备方法
Bechtel Standard of care for retinal vein occlusion may need to be reconsidered.
Oga et al. You're Getting on My Nerves
TW201417818A (zh) 曲安奈德眼用製劑及其製備方法
CN105935442A (zh) 一种治疗青光眼的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110831